News - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

Field Trip Health Ltd. Common Shares to Trade on the OTCQX Best Market

Field Trip Health Ltd. Common Shares to Trade on the OTCQX Best Market

Post published:January 28, 2021
Post category:Press Release

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

Post published:January 28, 2021
Post category:Press Release

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

Post published:January 28, 2021
Post category:Press Release

Mydecine Innovations Group Files Application to list to the NASDAQ

Mydecine Innovations Group Files Application to list to the NASDAQ

Post published:January 27, 2021
Post category:Press Release

NeonMind Appoints Robert Tessarolo as President and Chief Executive Officer

NeonMind Appoints Robert Tessarolo as President and Chief Executive Officer

Post published:January 27, 2021
Post category:Press Release

UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

Post published:January 27, 2021
Post category:Analysis News

Psyence Group to Commence Trading (CSE:PSYG) on January 27, 2021

Psyence Group to Commence Trading (CSE:PSYG) on January 27, 2021

Post published:January 26, 2021
Post category:Press Release

atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents

atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents

Post published:January 26, 2021
Post category:Press Release

Novamind Announces Marketing Services Agreements

Novamind Announces Marketing Services Agreements

Post published:January 26, 2021
Post category:Press Release

MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category

MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category

Post published:January 26, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.